TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05922267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACTIVE CYCLE OF BREATHING TECHNIQUES
Description: The participants in group A will be given ACBT with conventional chest physiotherapy .~Instruction for patient~* Try to keep your chest~* Take a long, slow and deep breath in, through your nose if you can.~* At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing~* Breathe out gently and relaxed, like a sigh. Don't force the air out.~* Repeat 3 - 5 times.~* If the patient feels light-headed then it is important that they revert back to the breathing control phase of the cycle~* Huffing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLOW EXPIRATION WITH OPEN GLOTTIS IN LATERAL POSITION
Description: The participants in group B will be given slow expiration with open glottis in lateral posture and conventional chest physiotherapy .In this technique, a patient adopts a lateral posture or a lateral decubitus posture. The affected lung is in the dependent position. A patient commences breathing normally, at tidal volumes. They are then instructed to perform a series of slow expirations with an open glottis. Expiration from functional residual capacity to the end of the expiratory reserve volume are encouraged to achieve maximum inflation . To assist in maintaining an open glottis, a mouthpiece may be used, to decrease the degree of airway compression A series of three ELTGOL may be performed, with each series composed of approximately 10 slow and deep expirations. In between each series of maneuvers, a rest period (around 1-2 minutes) is provided, with the patient staying in the same position. A typical treatment lasts for around 20 minutes
Study: NCT05121077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.
Study: NCT05474040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine versus multimodal analgesia for post elective craniotomy pain
Description: To compare the effectiveness of opioid- sparing multimodal analgesia and opioid analgesia in the treatment of post-craniotomy pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine versus multimodal analgesia for post elective craniotomy pain
Description: To compare the effectiveness of opioid- sparing multimodal analgesia and opioid analgesia in the treatment of post-craniotomy pain
Study: NCT06569290

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 phone calls
Description: 2 recruitment phone calls made by the call center

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 phone calls
Description: 2 recruitment phone calls made by the call center

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 phone calls
Description: 2 recruitment phone calls made by the call center

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 phone calls
Description: 2 recruitment phone calls made by the call center

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 phone calls
Description: 4 recruitment phone calls made by the call center

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 phone calls
Description: 4 recruitment phone calls made by the call center

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 phone calls
Description: 4 recruitment phone calls made by the call center

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 phone calls
Description: 4 recruitment phone calls made by the call center
Study: NCT05737030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate
Description: Amino acid combination
Study: NCT04864496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prescribe N-acetylcysteine tablets
Description: N-acetylcysteine tablets ,1200 mg two times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prescribe placebo tablets
Description: manufactured by Daroo Salamat Pharmed, two times daily
Study: NCT05950906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDM608
Description: PDM608 subcutaneous at single or multiple dose(s) assigned by cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDM608
Description: PDM608 subcutaneous at single or multiple dose(s) assigned by cohort

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous at single or multiple dose(s) to match PDM608 administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous at single or multiple dose(s) to match PDM608 administration.
Study: NCT05870501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5mg/kg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5mg/kg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 0.045mg/kg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 0.045mg/kg IV infusion
Study: NCT06003751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - Low Dose
Description: PER-001 Low Dose Intravitreal Implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - High Dose
Description: PER-001 High Dose Intravitreal Implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - Sham
Description: PER-001 Intravitreal Sham

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - Sham
Description: PER-001 Intravitreal Sham
Study: NCT05117710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ebselen
Description: Ebselen is an organoselenium compound, developed originally as an antioxidant for use in neuroprotection, post-stroke. Ebselen is a bioavailable and brain penetrant inhibitor of inositol monophosphatase (IMPase) (Ki ≈ 1 μM).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsules
Study: NCT05033444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRV-002
Description: SAD portion: Eligible participants will be randomized to receive a single ascending dose of PRV-002 on study Day 1. Dose escalation will be conducted in a total of 3 cohorts. Within each cohort, 6 participants will be randomized to receive a single dose of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.533 mg/kg (based on a 60kg participant) will be investigated.~MAD portion: Eligible participants will be randomized to receive a multiple (one dose per day for 5 consecutive days). Dose escalation will be conducted in a total of 2 cohorts. Within each cohort, 6 participants will be randomized to receive of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.266 mg/kg (based on a 60kg participant) will be investigated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
Study: NCT05427682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyroglutamate rongliflozin capsules
Description: Subjects will receive one 50mg capsule on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyroglutamate rongliflozin capsules
Description: Subjects will receive one 50mg capsule on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyroglutamate rongliflozin capsules
Description: Subjects will receive one 50mg capsule on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyroglutamate rongliflozin capsules
Description: Subjects will receive one 50mg capsule on Day 1
Study: NCT06025292

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lean Pork vs Plant-Based Protein
Description: Participants will eat prepared study meals for three days that have either protein sourced from lean pork or plant-based sources.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lean Pork vs Plant-Based Protein
Description: Participants will eat prepared study meals for three days that have either protein sourced from lean pork or plant-based sources.
Study: NCT05606822

Intervention type: OTHER
Intervention: Observational
Description: Collection of data from electronic health record

Intervention type: OTHER
Intervention: Observational
Description: Collection of data from electronic health record
Study: NCT04740593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthoptic care with the prescription of glasses from age 12-18 months onwards
Description: Children assigned to the intervention group (group 1) will receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, and glasses, based on accurate determinations of refractive error by retinoscopy in cycloplegia by the study orthoptists at age 12-18 months. The spectacles for the children in this study will be provided by the study via their optician without costs.

Intervention type: OTHER
Group type: OTHER
Intervention: Orthoptic care without the prescription of glasses from age 12-18 months onwards
Description: Children with high refractive error in the control group (group 2) will also receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, but they will not receive glasses.

Intervention type: OTHER
Group type: OTHER
Intervention: First measurement only
Description: Children who have no or mild refractive error (group 3), the majority of all children, will be examined by the study orthoptists only once at the age of 12-18 months, after which youth health care (YHC) physicians and nurses will continue standard vision screening at CHCs, as part of screening for general health disorders and vaccinations. Visual acuity is measured routinely at 42-48 months as part of standard vision screening.
Study: NCT05663086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose group
Description: The vaccines are to be administrated at day 0. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose group
Description: The vaccines are to be administrated at day 0. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: One dose group
Description: The vaccines are to be administrated at day 0. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses group
Description: The vaccines are to be administrated at day 0 and 28. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses group
Description: The vaccines are to be administrated at day 0 and 28. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Two doses group
Description: The vaccines are to be administrated at day 0 and 28. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aged 18-59 years
Description: The vaccines are to be administrated in the population of 18-59 years.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
Study: NCT05609019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2005
Description: Tablets. Take orally.
Study: NCT05674968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Challenging Behaviors in ADHD; Psychosocial program
Description: MCB-ADHD is a brief Behavioral Parent Training (BPT) program delivered to caregivers and children together. THe researchers have specially designed this program to be flexible so that it can be delivered over telehealth and/or in-person. All sessions are guided by web-based tool to provide parent support materials and direct the work to be completed in session. MCB-ADHD combines brief BPT skills modules adapted from an established evidence-based BPT called Helping the Noncompliant Child (HNC; McMahon \& Forehand, 2003) with high quality psychoeducation and advocacy training that were developed by the investigators specifically for use in this project. Families receive 4 sessions adapted from HNC focused on behavior management and 2 sessions focused on education and empowerment.
Study: NCT05441475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w
Description: All subjects will receive continuous oral administration of absk-011 once a day (QD) or twice a day (bid) with an initial dose of 180 mg, and intravenous infusion (IV) of 1200 mg of atilizumab every 21 days (q3w).
Study: NCT05470062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arch support insoles (FootDisc)
Description: The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
Study: NCT06438393

Intervention type: DIAGNOSTIC_TEST
Intervention: CT coronary angiography and non-contrast CT
Description: A CTCA is an X-ray computed tomography of the coronary arteries that allows visualization of coronary plaques with high temporal and spatial resolution, however, it implies the use of iodine contrast and exposition to clinically significant ionizing radiation.~Non-contrast ECG-gated CT (calcium score - CCS image). A non-contrast cardiac CT for CCS can be performed very quickly with significantly lower radiation (\~6 times lower) than CTCA and without the need for contrast.
Study: NCT05663086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aged 18-59 years
Description: The vaccines are to be administrated in the population of 18-59 years.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aged 18-59 years
Description: The vaccines are to be administrated in the population of 18-59 years.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aged 60 years old and above
Description: The vaccines are to be administrated in the population of 60 years old and above.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aged 60 years old and above
Description: The vaccines are to be administrated in the population of 60 years old and above.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aged 60 years old and above
Description: The vaccines are to be administrated in the population of 60 years old and above.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
Study: NCT06082947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS®
Description: CliniMACS® αβT cell/CD19+B cell depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
Study: NCT06653010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal CAR-T cells injection for treating mCRC
Description: A novel universal CAR-T platform to treat cancer patients
Study: NCT05387005

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: UBT
Description: H. pylori diagnostic test: C13 urea breath test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPSA
Description: H. pylori diagnostic test: H. pylori stool antigen test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: UBT and HPSA
Description: H. pylori diagnostic tests: H. pylori serology test, C13 urea breath test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serology (two stage)
Description: H. pylori diagnostic test: H. pylori serology test
Study: NCT05963425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: This physical activity program will be based only on the work of basic physical traininig, in which specifically and mainly the strength and resistance will be worked, but also flexibility

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: This physical activity program will be based only on the work of basic physical traininig, in which specifically and mainly the strength and resistance will be worked, but also flexibility

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual clinical practice
Description: usual clinical practice
Study: NCT05334381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted-STAT ED
Description: Patient navigator assigned to provide culturally informed motivational interviews, brief case management, psychoeducation and telephone contacts
Study: NCT05011422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
Description: Once pheresed, the product will be washed to remove platelets and the cell concentration will be adjusted per laboratory and ClinicMACS technology recommendations. It is then labeled using the CliniMACS αβ-TCR Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product
Study: NCT04891250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Treatment of SARS Cov-2 patients with Ivermectin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Description: Treatment of high risk population with Ivermectin as prophylaxis
Study: NCT05189015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: - Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Description: - Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
Study: NCT06672172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 tablet
Description: HRS-7535 tablet; low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 tablet
Description: HRS-7535 tablet; middle dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 tablet
Description: HRS-7535 tablet; high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS-7535 placebo tablet
Description: HRS-7535 placebo tablet
Study: NCT06672380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Physical Exercise Program for Breast Cancer Survivors
Description: Structured and remotely guided physical exercise program The participants in the intervention group took part in a remote physical exercise program for 12 weeks. The telepresence sessions, conducted three times a week via Google Meet®, lasted 60 minutes and consisted of three phases: warm-up (10 minutes), multi-joint functional exercises (40 minutes) and stretching (10 minutes). The exercises were progressively intensified over the weeks, using the Borg scale to monitor effort. The intensity was adjusted in three cycles: in the first 4 weeks (60 seconds of exercise/90 seconds of rest), in weeks 5 to 8 (75 seconds of exercise/60 seconds of rest) and in weeks 9 to 12 (90 seconds of exercise/30 seconds of rest).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial Consultation and Exercise Guidance via Ebook for Women Surviving Breast Cance
Description: Participants in the Ebook group received an illustrated manual containing detailed guidelines for practicing simple physical exercises at home, using only their body weight. The manual suggested a frequency of 3 to 5 times a week, with 30 to 60 minutes of activities such as stretching, squats and exercises for the upper and lower limbs. The participants were encouraged to follow these guidelines and, 30 days after receiving the ebook, an additional stimulus was sent by text message, reinforcing the importance of following the protocol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Initial Incentive for Eating Habits in Women Surviving Breast Cancer
Description: The control group only received general guidance on the importance of regular physical activity. The recommendations followed health guidelines, suggesting between 150 and 300 minutes of moderate-intensity physical activity per week.
Study: NCT06672315

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transesophageal echocardiography
Description: Confirmation of chest compression positioning via transesophageal echocardiography (TEE)
Study: NCT06687174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: MY008211A BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: MY008211A BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MY008211A tablets matched placebo
Description: Matching placebo to MY008211A taken twice a day.